

wherein:

R^1 is selected from the group consisting of hydrogen, halogen, cyano, C_1 - C_6 -alkyl, trifluoromethyl, C_3 - C_8 -cycloalkyl, C_1 - C_4 -hydroxyalkyl, hydroxy, C_1 - C_4 -alkoxy, benzyloxy, C_2 - C_4 -alkanoyloxy, C_1 - C_4 -alkylthio, C_2 - C_5 -alkoxycarbonyl, aminocarbonyl, C_3 - C_9 -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy, NR^5R^6 , and bridged R^1R^2 wherein

R^5 is selected from the group consisting of hydrogen and C_1 - C_6 -alkyl; and

R^6 is selected from the group consisting of hydrogen and C_1 - C_6 -alkyl;

R^2 is selected from the group consisting of hydrogen, halogen, C_1 - C_6 -alkyl, trifluoromethyl and hydroxy and bridged R^1R^2 ;

wherein

bridged R^1R^2 is where R^1R^2 are adjacent and form a bridge which is selected from the group consisting of $-(CH_2)_4-$, $-(CH=CH)_2-$ and $-CH_2O-CR^7R^8-O-$; wherein

R^7 is selected from the group consisting of hydrogen, and

C₁-C₆-alkyl; and

R⁸ is selected from the group consisting of hydrogen and

C₁-C₆-alkyl;

(P) R³ is selected from the group consisting of hydrogen, halogen and C₁-C₆-alkyl;

R⁴ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, hydroxy, C₁-C₆-alkoxy and benzyloxy;

k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted one to three-fold by C₁-C₃-alkyl, hydroxy, fluorine, cyano, or phenyl, C₄-C₆-alkadienylene,

a substituted C₄-C₆-alkadienylene which is substituted once or twice by C₁-C₃-alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C₁-C₃-alkyl, fluorine, or cyano, and ethinylene;

D is selected from the group consisting of

C₁-C₁₀-alkylene,

a substituted C₁-C₁₀-alkylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

C₂-C₁₀-alkenylene,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

a C₂-C₁₀-alkenylene wherein the double bond is to ring E,

a substituted C₂-C₁₀-alkenylene which is substituted once

or twice by C₁-C₃-alkyl or hydroxy, wherein the double bond is to E,


A/ C₃-C₁₀-alkinylene,

a substituted C₃-C₁₀-alkinylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

a C₁ to C₁₀ group selected from the group consisting of C₁-C₁₀-alkylene, C₂-C₁₀-alkenylene and C₃-C₁₀-alkinylene, the C₁ to C₁₀ group having methylene units wherein one to three of the methylene units are isosterically replaced by O, S, NR⁹, CO, SO or SO₂; wherein

R⁹ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, C₂-C₆-acyl and methanesulfonyl;

E is



wherein n and p are, independent of each other, 0, 1, 2, or 3, wherein n + p ≤ 3,

R¹⁰ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, hydroxy, hydroxymethyl, carboxy and C₂-C₇-alkoxycarbonyl;

R¹¹ is selected from the group consisting of hydrogen and

an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen,
G1, G2, G3, G4 and G5; wherein

P1
G1 is $-(CH_2)_r-(CR^{13}R^{14})_s-R^{12}$

wherein

r is 0, 1 or 2, and

s is 0 or 1,

R¹² is selected from the group consisting of
hydrogen,

C₁-C₆-alkyl,

C₃-C₆-alkenyl,

C₃-C₆-alkinyl,

C₃-C₈-cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles
which heterocycles contain one to three hetero-atoms selected
from the group consisting of N, S and O, which heterocycles
are either bound directly to or over a methylene group,

an anellated bi- and tricyclic aromatic or partially
hydrogenated carbocyclic ring system with 8 to 16 ring atoms
and at least one aromatic ring and the carbocyclic ring and
aromatic ring being bonded with a bond which is either over an
aromatic or a hydrogenated ring and either directly or over a
methylene group, and

an anellated bi- and tricyclic aromatic or partially
hydrogenated heterocyclic ring systems with 8 to 16 ring atoms

and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group;

R¹³ has the same meaning as R¹², but is selected independently thereof,



R¹⁴ is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,

monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,


an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

an anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group;

G2 is selected from the group consisting of



and



wherein R^{12} and R^{14} have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,


saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, and

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is $-\text{SO}_2-(\text{CH}_2)_x-\text{R}^{12}$,

G4 is



wherein

Ar^1 is selected from the group consisting of phenyl, pridyl and naphthyl; and

Ar^2 is selected from the group consisting of phenyl, pyridyl and naphthyl;

G5 is $-\text{COR}^{15}$,

wherein

R^{15} is selected from the group consisting of trifluoromethyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_3\text{-C}_6$ -alkenyloxy and benzyloxy; and

wherein aromatic rings in R^1 , R^4 , R^{12} , R^{13} , R^{14} , R^{15} , Q , Ar^1 and Ar^2 are unsubstituted or substituted, the substituted rings in R^1 , R^4 , R^{12} , R^{13} , R^{14} , R^{15} , Q , Ar^1 and Ar^2 having one to three substituents which are independently selected from the group consisting of halogen, cyano, $\text{C}_1\text{-C}_6$ -alkyl, trifluoromethyl, $\text{C}_3\text{-C}_8$ -cycloalkyl, phenyl, benzyl, hydroxy, $\text{C}_1\text{-C}_6$ -alkoxy, and a substituted $\text{C}_1\text{-C}_6$ -alkoxy which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, $\text{C}_1\text{-C}_6$ -

alkylthio, carboxy, C₂-C₆-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C₁-C₆-alkylamino, and di-(C₁-C₆-alkyl)-amino, wherein general formula (I) does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-yl)ethyl]-2-propenamide.

P/ 43. (Twice amended) A compound according to claim 42, wherein:

R¹ is selected from the group consisting of hydrogen, halogen, cyano, methyl, trifluoromethyl, hydroxy, C₁-C₄-alkoxy, ethylthio, methoxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, carboxy, and phenoxy,

R² is selected from the group consisting of hydrogen, halogen, trifluoromethyl and hydroxy,

R³ is hydrogen or halogen,

R⁴ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, hydroxy and C₁-C₃-alkoxy,

k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted once or twice by C₁-C₃-alkyl, hydroxy or fluorine,

a C₄-C₆-alkadienylene,

a substituted C₄-C₆-alkadienylene which is substituted by C₁-C₃-alkyl or by 1 or 2 fluorine atoms,

1,3,5-hexatrienylene, and

a substituted 1,3,5-hexatrienylene which is substituted

by fluorine,

D is selected from the group consisting of C₁-C₈-alkylene,

B1
a substituted C₁-C₈-alkylene which is substituted once or twice by methyl or hydroxy,

C₂-C₈-alkenylene,

a substituted C₂-C₈-alkenylene which is substituted once or twice by methyl or hydroxy,


an E double bonded substituted C₂-C₈-alkenylene which has a double bond to ring E,

C₃-C₈-alkinylene,

a substituted C₃-C₈-alkinylene which is substituted once or twice by methyl or hydroxy, and

a C₁ to C₈ group selected from the group consisting of C₁-C₈-alkylene, C₂-C₈-alkenylene and C₃-C₈-alkinylene, the C₁ to C₈ group having methylene units wherein one to three methylene units are isosterically replaced by O, S, NH, N(CH₃), N(COCH₃), N(SO₂CH₃), CO, SO or SO₂,

E is



wherein n and p are, independent of each other, 0, 1, 2, or 3, wherein n + p ≤ 3,

R¹⁰ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, hydroxy, hydroxymethyl, carboxy and C₂-C₇-alkoxycarbonyl;

D
R¹¹ is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen, G1, G2, G3, G4 and G5; wherein

G1 is -(CH₂)_r-(CR¹³R¹⁴)_s-R¹²

wherein

r is 0, 1 or 2, and

s is 0 or 1,

R¹² is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₈-cycloalkyl, benzyl, phenyl, benzocyclobutyl, indanyl, indenyl, oxoindanyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, oxotetrahydronaphthyl, biphenylenyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, phenanthryl, dihydrophenanthryl, oxodihydrophenanthryl, dibenzocycloheptenyl, oxodibenzocycloheptenyl, dihydribenzocycloheptenyl, oxodihydribenzocycloheptenyl, dihydribenzocyclooctenyl, tetrahydribenzocyclooctenyl, oxotetrahydribenzocyclooctenyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, imidazothiazolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, dihydrobenzothienyl, indolyl, indolinyl, oxoindolinyl,



R¹ | dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl,
benzisoxazolyl, oxobenzisoxazolinyl, benzothiazolyl,
oxobenzthiazolinyl, benzoisothiazolyl, oxobenzoisothiazolinyl,
benzimidazolyl, oxobenzimidazolinyl, indazolyl,
oxoindazolinyl, benzofurazanyl, benzothiadiazolyl,
benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl,
thiazolopyridyl, oxodihydrothiazolopyridyl,
isothiazolopyridyl, imidazopyridyl, oxodihydroimidazopyridyl,
pyrazolopyridyl, oxodihydropyrazolopyridyl, thienopyrimidinyl,
chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl,
isoquinolyl, dihydroquinolyl, oxodihydroquinolyl,
tetrahydroquinolyl, oxotetrahydroquinolyl, benzodioxanyl,
quinoxalinyl, quinazolinyl, naphthyridinyl, carbazolyl,
tetrahydrocarbazolyl, oxotetrahydrocarbazolyl, pyridoindolyl,
acridinyl, oxodihydroacridinyl, phenothiazinyl,
dihydrodibenzoxepinyl, oxodihydrodibenzoxepinyl,
benzocycloheptathienyl, oxobenzocycloheptathienyl,
dihydrothienobenzothiepinyl, oxodihydrothienobenzothiepinyl,
dihydrodibenzothiepinyl, oxodihydrodibenzothiepinyl,
octahydrodibenzothiepinyl, dihydronazepinyl,
oxodihydrodibenzazepinyl, octahydrodibenzazepinyl,
benzocycloheptapyridyl, oxobenzocycloheptapyridyl,
dihdropyridobenzodiazepinyl, dihydrodibenzoxazepinyl,
dihdropyridobenzoxepinyl, dihydropyridobenzoxazepinyl,
oxodihdropyridobenzoxazepinyl, dihydrodibenzothiazepinyl,
oxodihydrodibenzothiazepinyl, dihydropyridobenzothiazepinyl,
and oxodihdropyridobenzothiazepinyl,

R¹³ has the same meaning as R¹², but is selected
independently therefrom,


R¹⁴ is selected from the group consisting of hydrogen,

hydroxy, methyl, benzyl, phenyl, indanyl, indenyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, triazinyl, benzofuryl, benzothienyl, indolyl, indolinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, chromanyl, quinolyl, and tetrahydroquinolyl,

G2 is selected from the group consisting of



and




wherein R¹² and R¹⁴ have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of azetidine, pyrrolidine, piperidine, (1H)tetrahydropyridine, hexahydroazepine, (1H)tetrahydroazepine, octahydroazocine, pyrazolidine, piperazine, hexahydrodiazepine, morpholine, hexahydroooxazepine, thiomorpholine, thiomorpholine-1,1-

P)

dioxide, 5-aza-bicyclo[2.1.1]hexane, 2-aza-bicyclo[2.2.1]heptane, 7-aza-bicyclo[2.2.1]heptane, 2,5-diaza-bicyclo[2.2.1]heptane, 2-aza-bicyclo[2.2.2]octane, 8-aza-bicyclo[3.2.1]octane, 2,5-diazabicyclo[2.2.2]octane, 9-azabicyclo[3.3.1]nonane, indoline, isoindoline, (1H)-dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydroquinoxaline, (4H)-dihydrobenzoxazine, (4H)-dihydrobenzothiazine, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[c]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, (10H)-dihydroacridine, 1,2,3,4-tetrahydroacridanone, (10H)-phenoxazine, (10H)-phenothiazine, (5H)-dibenzazepine, (5H)-dihydrodibenzazepine, (5H)-octahydrodibenzazepine, (5H)-dihydrodibenzodiazepine, (11H)-dihydrodibenzo[b,e]oxazepine, (11H)-dihydrodibenzo[b,e]thiazepine, (10H)-dihydrodibenzo[b,f]oxazepine, (10H)-dihydrodibenzo[b,f]thiazepine, and (5H)-tetrahydrodibenzazocine,

G3 is $-\text{SO}_2-(\text{CH}_2)_r-\text{R}^{12}$,

G4 is



wherein

Ar¹ and

Ar² are selected independently of each other from the group consisting of phenyl, pyridyl and naphthyl;

G5 is -COR¹⁵,

wherein

R¹⁵ is selected from the group consisting of trifluoromethyl, C₁-C₆-alkoxy, C₃-C₆-alkenyloxy and benzyloxy; and

wherein aromatic rings are substituted or unsubstituted independently of each other by one to three substituents which are independently selected from the group consisting of halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl, benzyl, hydroxy, C₁-C₆-alkoxy, and a substituted C₁-C₆-alkoxy which is entirely or partially substituted by fluorine; benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, carboxy, C₂-C₆-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C₁-C₆-alkylamino, and di-(C₁-C₆-alkyl)-amino.

44. (Twice amended) A compound according to claim 43
wherein:

R¹ is selected from the group consisting of hydrogen, halogen, cyano, methyl, trifluoromethyl, hydroxy, methoxy and methoxycarbonyl,

R² is hydrogen or halogen,

R³ is hydrogen,

R⁴ is selected from the group consisting of hydrogen, C₁-C₃-alkyl and hydroxy,

A¹
k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted once or twice by hydroxy or fluorine,

C₄-C₆-alkadienylene,

a substituted C₄-C₆-alkadienylene which is substituted by one or two fluorine atoms, and

1,3,5-hexatrienylene

D is selected from the group consisting of C₂-C₈-alkylene,

a substituted C₂-C₈-alkylene which is substituted by methyl or hydroxy

C₂-C₈-alkenylene,


a substituted C₂-C₈-alkenylene which is substituted by methyl or hydroxy,

a C₂-C₈-alkenylene wherein the double bond is to ring E,

a substituted C₂-C₈-alkenylene which is substituted by methyl or hydroxy, wherein the double bond is to ring E,

a C₂ to C₈ group selected from the group consisting of C₂-C₈-alkylene and C₂-C₈-alkenylene, the C₂ to C₈ group having methylene units wherein one to three of the methylene units are isosterically replaced by O, NH, N(CH₃), N(COCH₃), N(SO₂CH₃) or CO,

E is



P
I

wherein n and p are, independent of each other, 0, 1, 2, or 3, wherein $n + p \leq 3$,

R^{10} is selected from the group consisting of hydrogen, methyl and hydroxyl,

R^{11} is hydrogen or an oxo group adjacent to the nitrogen atom,

G is selected from the group consisting of hydrogen, $\text{C}_3\text{-C}_8$ -cycloalkyl, methoxycarbonyl, tert-butoxycarbonyl, benzyloxycarbonyl, trifluoroacetyl, diphenylphosphinoyl,

- $(\text{CH}_2)_r - (\text{CR}^{13}\text{R}^{14})_s - \text{R}^{12}$,

- $\begin{array}{c} \text{C} \\ \parallel \\ \text{O} \end{array} - (\text{CH}_2)_r - (\text{CR}^{13}\text{R}^{14})_s - \text{R}^{12}$,

- $\begin{array}{c} \text{C} \\ \parallel \\ \text{O} \end{array} - (\text{CH}_2)_r - \text{NR}^{12}\text{R}^{14}$,

and

- $\text{SO}_2 - (\text{CH}_2)_r \text{R}^{12}$,

wherein

r is 0, 1 or 2,

s is 0 or 1,


*R*¹² is selected from the group consisting of hydrogen, methyl, benzyl, phenyl, indanyl, indenyl, oxoindanyl, naphthyl, dihydronaphthyl, tetrahydronaphthyl, oxotetrahydronaphthyl, flourenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, dibenzocycloheptenyl, oxodibenzocycloheptenyl, dihydromibenzocycloheptenyl, oxodihydromibenzocycloheptenyl bound directly or over a methylene group, furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, dihydrobenzofuryl, benzothienyl, dihydrobenzothienyl, indolyl, indolinyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl, benzisoxazolyl, oxobenzisoxazolinyl, benzothiazolyl, oxobenzthiazolinyl, benzoisothiazolyl, oxobenzoisothiazolinyl, benzimidazolyl, oxobenzimidazolinyl, benzofurazanyl, benzothiadiazolyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, isothiazolopyridyl, imidazopyridyl, oxodihydroimidazopyridyl, pyrazolopyridyl, thienopyrimidinyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, dihydroquinolyl, oxodihydroquinolinyl, tetrahydroquinolyl, oxotetrahydroquinolinyl, benzodioxanyl, quinoxalinyl, quinazolinyl, naphthyridinyl, carbazolyl, tetrahydrocarbazolyl, oxotetrahydrocarbazolyl, pyridoindolyl,

P1
acridinyl, oxodihydroacridinyl, phenothiazinyl,
dihydrodibenzoxepinyl, benzocycloheptathienyl,
oxobenzocycloheptathienyl, dihydrothienobenzothiepinyl,
oxodihydrothienobenzothiepinyl, dihydrodibenzothiepinyl,
oxodihydrodibenzothiepinyl, dihydrodibenzazepinyl,
oxodihydrodibenzazepinyl, octahydrodibenzazepinyl,
benzocycloheptapyridyl, oxobenzocycloheptapyridyl,
dihdropyridobenzoxepinyl, dihydrodibenzothiazepinyl, and
oxodihydrodibenzothiazepinyl,

R¹³ is selected from the group consisting of hydrogen,
methyl, benzyl and phenyl,

R¹⁴ is selected from the group consisting of hydrogen,
hydroxy, methyl, benzyl, phenyl, naphthyl, furyl, thienyl,
oxazolyl, thiazolyl, pyrazolyl, imidazolyl, oxadiazolyl,
thiadiazolyl, pyridyl, benzofuryl, benzothienyl, indolyl,
indolinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl,
chromanyl, quinolyl and tetrahydroquinolyl,

wherein in formula



-NR¹²R¹⁴ may be selected from the group consisting of
pyrrolidine, piperidine, (1H)-tetrahydropyridine,
hexahydroazepine, octahydroazocine, piperazine,
hexahydrodiazepine, morpholine, hexahydrooxazepine, 2-
azabicyclo[2.2.1]heptane, 7-azabicyclo[2.2.1]heptane, 2,5-
diazabicyclo[2.2.1]heptane, 8-azabicyclo[3.2.1]octane, 2,5-
diazabicyclo[2.2.2]octane, indoline, isoindoline, (1H)-
dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-

P /
tetrahydroisoquinoline, (1H)-tetrahydroquinoxaline, (4H)-dihydrobenzoxazine, (4H)-dihydrobenzothiazine, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, (10H)-dihydroacridine, 1,2,3,4-tetrahydroacridanone, (5H)-dihydrodibenzazepine, (5H)-dihydrodibenzodiazepine, (11H)-dihydrodibenzo[b,e]oxazepine, (11H)-dihydrodibenzo[b,e]thiazepine, (10H)-dihydrodibenzo[b,f]oxazepine and (5H)-tetrahydrodibenzazocine,

wherein aromatic rings are substituted or unsubstituted independently of each other by one to three substituents independently selected from the group consisting of halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl, benzyl, hydroxy, C₁-C₆-alkoxy, and a substituted C₁-C₆-alkoxy entirely or partially substituted by fluorine; benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, carboxy, C₂-C₆-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C₁-C₆-alkylamino, and di-(C₁-C₆-alkyl)-amino.

45. (Twice amended) A compound according to claim 44,
wherein

R¹ is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl and hydroxy,

R² and

R³ are hydrogen,

R⁴ is hydrogen or hydroxy,

k is 0 or 1,

D A is selected from the group consisting of C₂-C₄-alkenylene,

1,3-butadienylene,

a C₂-C₄-alkenylene substituted by fluorine, and


a 1,3-butadienylene substituted by fluorine,



D is selected from the group consisting of C₂-C₆-alkylene, C₂-C₆-alkenylene, and C₂-C₆-alkenylene wherein the double bond of the C₂-C₆-alkenylene is to ring E, and

a C₂ to C₆ group selected from the group consisting of C₂-C₆-alkylene and C₂-C₆-alkenylene, the C₂ to C₆ group having a methylene unit, wherein the methylene unit is isosterically replaced by O, NH, N(CH₃) or CO, or the C₂ to C₆ group having an ethylene group which is isosterically replaced by NH-CO or CO-NH, or the C₂ to C₆ group having a propylene group which is isosterically replaced by NH-CO-O or O-CO-NH,


E is selected from the group consisting of piperidine, and a substituted piperidine wherein the heterocyclic ring is substituted by an oxo group adjacent to the nitrogen atom,

G is selected from the group consisting of hydrogen, tert-butoxycarbonyl, diphenylphosphinoyl,





and



wherein

r is 0 or 1,

s is 0 or 1,

R^{12} is selected from the group consisting of hydrogen, methyl, benzyl, phenyl, indenyl, oxoindanyl, naphthyl, tetrahydronaphthyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, dibenzocycloheptenyl, and dihydrodibenzocycloheptenyl, bound directly or over a methylene group, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, benzothienyl, indolyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl, benzothiazolyl, oxobenzthiazolinyl, benzimidazolyl, oxobenzimidazolinyl, benzofurazanyl, benzotriazolyl, oxazolopyridyl,


P1

oxodihydrooxazolopyridyl, thiazolopyridyl,
 oxodihydrothiazolopyridyl, chromanyl, chromanonyl,
 benzopyranyl, chromanyl, quinolyl, isoquinolyl,
 oxodihydroquinolinyl, tetrahydroquinolyl,
 oxotetrahydroquinolinyl, benzodioxanyl, quinazolinyl,
 acridinyl, oxodihydroacridinyl, phenothiazinyl,
 dihydronbenzoxepinyl, benzocycloheptathienyl,
 dihydrothienobenzothiepinyl, dihydronbenzothiepinyl,
 oxodihydronbenzothiepinyl, dihydronbenzazepinyl,
 oxodihydronbenzazepinyl, octahydronbenzazepinyl,
 benzocycloheptapyridyl, oxobenzocycloheptapyridyl, and
 dihydronbenzothiazepinyl,

R^{13} is selected from the group consisting of hydrogen,
 methyl, benzyl and phenyl,

R^{14} is selected from the group consisting of hydrogen,
 hydroxy, methyl, benzyl, phenyl, naphthyl, furyl, thiethyl,
 pyridyl, benzofuryl, benzothienyl, indolyl, benzoxazolyl,
 benzothiazolyl, benzimidazolyl, chromanyl, quinolyl and
 tetrahydroquinolyl,

wherein in the formula



(G2b)

$-\text{NR}^{12}\text{R}^{14}$ may be selected from pyrrolidine, piperidine,
 hexahydroazepine, morpholine, 2,5-diazabicyclo[2.2.1]heptane,
 indoline, isoindoline, (1H)-dihydroquinoline, (1H)-

tetrahydroquinoline, (2H)-tetrahydroisoquinoline, (1H)-tetrahydrobenzo[b]azepine, (1H)-tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine, (5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-tetrahydroacridanone, (5H)-dihydrodibenzazepine, (11H)-dihydrodibenzo[b,e]oxazepine and (11H)-dihydrodibenzo[b,e]thiazepine,

wherein aromatic rings are substituted or unsubstituted, independently of each other, by one to three substituents which are independently selected from the group consisting of halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl, benzyl, hydroxy, C₁-C₆-alkoxy, a substituted C₁-C₆-alkoxy which is entirely or partially substituted by fluorine; benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, carboxy, C₂-C₆-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C₁-C₆-alkylamino and di-(C₁-C₆-alkyl)-amino.

46. (Twice amended) A compound according to claim 45, wherein:

R¹ is selected from the group consisting of hydrogen, fluorine, methyl, trifluoromethyl and hydroxy,

R² and

R³ are hydrogen,

R⁴ is hydrogen or hydroxy,

k is 0,

A is ethenylene or 1,3-butadienylene

D is selected from the group consisting of C₂-C₆-alkylene, C₂-C₆-alkenylene, and a C₂-C₆-alkenylene wherein the

double bond of the C₂-C₆-alkenylene is to ring E,

E is selected from the group consisting of pyrrolidine, piperidine, hexahydroazepine and morpholine,

G is selected from the group consisting of benzyl, phenethyl, fluorenylmethyl, anthrylmethyl, diphenylmethyl, fluorenyl, dihydrodibenzocycloheptenyl, furylmethyl, thienylmethyl, thiazolylmethyl, pyridylmethyl, benzothienylmethyl, quinolylmethyl, phenyl-thienylmethyl, phenyl-pyridylmethyl, dihydrodibenzoepinyl, dihydrodibenzothiepinyl, acetyl, pivaloyl, phenylacetyl, diphenylacetyl, diphenylpropionyl, naphthylacetyl, benzoyl, naphthoyl, anthrylcarbonyl, oxofluorenylcarbonyl, oxodihydroanthrylcarbonyl, dioxodihydroanthrylcarbonyl, furoyl, pyridylcarbonyl, chromonylcarbonyl, quinolylcarbonyl, naphthylaminocarbonyl, dibenzylaminocarbonyl, benzylphenylaminocarbonyl, diphenylaminocarbonyl, indolinyl-1-carbonyl, dihydrodibenzazepin-N-carbonyl, tetrahydroquinolinyl-N-carbonyl, tetrahydrobenzo[b]azepinyl-N-carbonyl, methanesulfonyl, phenylsulfonyl, p-toluenesulfonyl, naphthylsulfonyl, quinolinsulfonyl, and diphenylphosphinoyl,


wherein aromatic rings are substituted or unsubstituted independently of each other by one to three substituents which are independently selected from the group consisting of halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl, benzyl, hydroxy, C₁-C₆-alkoxy, C₁-C₆-alkoxy, entirely or partially substituted by fluorine;

P1

benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, carboxy, C₂-C₆-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C₁-C₆-alkylamino and di-(C₁-C₆-alkyl)-amino, wherein two adjacent groups in the ring or ring system may form an additional ring over a methylenedioxy bridge.

P2

56. (Twice amended) A pharmaceutical composition comprising one or more of the compounds according to formula (I) and pharmaceutically acceptable acid addition salts of formula (I)



wherein:

R¹ is selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, C₁-C₄-hydroxyalkyl, hydroxy, C₁-C₄-alkoxy, benzyloxy, C₂-C₄-alkanoyloxy, C₁-C₄-alkylthio, C₂-C₅-alkoxycarbonyl, aminocarbonyl, C₃-C₉-dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy, NR⁵R⁶, and bridged R¹R²; wherein

R⁵ is selected from the group consisting of hydrogen and C₁-C₆-alkyl; and

R⁶ is selected from the group consisting of hydrogen and C₁-C₆-alkyl;

R² is selected from the group consisting of hydrogen, halogen, C₁-C₆-alkyl, trifluoromethyl and hydroxy and bridged R¹R²;

P²

wherein

bridged R¹R² is where R¹R² are adjacent and form a bridge which is selected from the group consisting of - (CH₂)₄ -, - (CH=CH)₂ - and -CH₂O-CR⁷R⁸-O-; wherein

R⁷ is selected from the group consisting of hydrogen, and C₁-C₆-alkyl; and

R⁸ is selected from the group consisting of hydrogen and C₁-C₆-alkyl;

R³ is selected from the group consisting of hydrogen, halogen and C₁-C₆-alkyl;

R⁴ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, hydroxy, C₁-C₆-alkoxy and benzyloxy;

k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted one to three-fold by C₁-C₃-alkyl, hydroxy, fluorine, cyano, or phenyl, C₄-C₆-alkadienylene,

a substituted C₄-C₆-alkadienylene which is substituted once or twice by C₁-C₃-alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C₁-C₃-alkyl, fluorine, or cyano, and ethinylene;

D is selected from the group consisting of

C₁-C₁₀-alkylene,

P2
a substituted C₁-C₁₀-alkylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

C₂-C₁₀-alkenylene,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

a C₂-C₁₀-alkenylene wherein the double bond is to E,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy, wherein the double bond is to E,


C₃-C₁₀-alkinylene,

a substituted C₃-C₁₀-alkinylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

an isosterically replaced C₁ to C₁₀ group selected from the group consisting of C₁-C₁₀-alkylene, C₂-C₁₀-alkenylene and C₃-C₁₀-alkinylene, the isosterically replaced C₁ to C₁₀ group having methylene units and one to three of the methylene units are isosterically replaced by O, S, NR⁹, CO, SO or SO₂; wherein

R⁹ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, C₂-C₆-acyl and methanesulfonyl;

E is



wherein n and p are, independent of each other, 0, 1, 2, or 3 wherein n + p ≤ 3,

P²
R¹⁰ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, hydroxy, hydroxymethyl, carboxy and C₂-C₇-alkoxycarbonyl;

R¹¹ is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen, G1, G2, G3, G4 and G5; wherein

G1 is -(CH₂)_r-(CR¹³R¹⁴)_s-R¹²

wherein

r is 0, 1 or 2, and

s is 0 or 1,

R¹² is selected from the group consisting of hydrogen,

C₁-C₆-alkyl,

C₃-C₆-alkenyl,

C₃-C₆-alkinyl,

C₃-C₈-cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected from the group consisting of N, S and O,

an anellated bi- and tricyclic aromatic or partially

hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, and

P²
an anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O;

R¹³ has the same meaning as R¹², but is selected independently thereof;


R¹⁴ is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,


monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, and


an anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms selected from N, S and O;

G2 is selected from the group consisting of





2
and



wherein R¹² and R¹⁴ have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,


saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms;

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is -SO₂- (CH₂)_r-R¹²,

G4 is

*P²*

wherein

Ar^1 is selected from the group consisting of phenyl, pridyl and naphthyl; and

Ar^2 is selected from the group consisting of phenyl, pyridyl and naphthyl;

G5 is $-\text{COR}^{15}$,

wherein


R^{15} is selected from the group consisting of trifluoromethyl, $\text{C}_1\text{-C}_6$ -alkoxy, $\text{C}_3\text{-C}_6$ -alkenyloxy and benzyloxy; and

wherein aromatic rings in R^1 , R^4 , R^{12} , R^{13} , R^{14} , R^{15} , Q, Ar^1 and Ar^2 are unsubstituted or substituted, the substituted rings in R^1 , R^4 , R^{12} , R^{13} , R^{14} , R^{15} , Q, Ar^1 and Ar^2 having one to three substituents which are independently selected from the group consisting of halogen, cyano, $\text{C}_1\text{-C}_6$ -alkyl, trifluoromethyl, $\text{C}_3\text{-C}_8$ -cycloalkyl, phenyl, benzyl, hydroxy, $\text{C}_1\text{-C}_6$ -alkoxy, and a substituted $\text{C}_1\text{-C}_6$ -alkoxy which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, $\text{C}_1\text{-C}_6$ -alkylthio, carboxy, $\text{C}_2\text{-C}_6$ -alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono- $\text{C}_1\text{-C}_6$ -alkylamino, and di-($\text{C}_1\text{-C}_6$ -alkyl)-amino,

wherein general formula (I) does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-yl)ethyl]-2-propenamide.

R³

64. (once amended) A method of inhibiting tumor cell growth in a human or animal body comprising administering to the human or animal body in need thereof an amount of a pharmaceutical composition effective for inhibiting tumor cell growth, wherein the pharmaceutical composition includes a compound of general formula (I)



wherein:

R^1 is selected from the group consisting of hydrogen, halogen, cyano, C_1 - C_6 -alkyl, trifluoromethyl, C_3 - C_8 -cycloalkyl, C_1 - C_4 -hydroxyalkyl, hydroxy, C_1 - C_4 -alkoxy, benzyloxy, C_2 - C_4 -alkanoyloxy, C_1 - C_4 -alkylthio, C_2 - C_5 -alkoxycarbonyl, aminocarbonyl, C_3 - C_9 -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy, NR^5R^6 , and bridged R^1R^2 ; wherein

R^5 is selected from the group consisting of hydrogen and C_1 - C_6 -alkyl; and

R^6 is selected from the group consisting of hydrogen and C_1 - C_6 -alkyl;

R^2 is selected from the group consisting of hydrogen, halogen, C_1 - C_6 -alkyl, trifluoromethyl and hydroxy and bridged R^1R^2 ;

wherein

*D*³
bridged R¹R² is where R¹R² are adjacent and form a bridge which is selected from the group consisting of - (CH₂)₄-, - (CH=CH)₂- and -CH₂O-CR⁷R⁸-O-; wherein

R⁷ is selected from the group consisting of hydrogen, and C₁-C₆-alkyl; and

R⁸ is selected from the group consisting of hydrogen and C₁-C₆-alkyl;

R³ is selected from the group consisting of hydrogen, halogen and C₁-C₆-alkyl;

R⁴ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, hydroxy, C₁-C₆-alkoxy and benzyloxy;

k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted one to three-fold by C₁-C₃-alkyl, hydroxy, fluorine, cyano, or phenyl,

C₄-C₆-alkadienylene,

a substituted C₄-C₆-alkadienylene which is substituted once or twice by C₁-C₃-alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C₁-C₃-alkyl, fluorine, or cyano, and ethinylene;

D is selected from the group consisting of

C₁-C₁₀-alkylene,

*R*³ a substituted C₁-C₁₀-alkylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

C₂-C₁₀-alkenylene,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

a C₂-C₁₀-alkenylene wherein the double bond is to E,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy, wherein the double bond is to E,


C₃-C₁₀-alkinylene,

a substituted C₃-C₁₀-alkinylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

a C₁ to C₁₀ group selected from the group consisting of C₁-C₁₀-alkylene, C₂-C₁₀-alkenylene and C₃-C₁₀-alkinylene, the C₁ to C₁₀ group having methylene units wherein one to three of the methylene units are isostERICALLY replaced by O, S, NR⁹, CO, SO or SO₂; wherein

R⁹ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, C₂-C₆-acyl and methanesulfonyl;

E is



wherein n and p are, independent of each other, 0, 1, 2,

or 3 wherein n + p ≤ 3,

*D*³
 R^{10} is selected from the group consisting of hydrogen, C₁-C₃-alkyl, hydroxy, hydroxymethyl, carboxy and C₂-C₇-alkoxycarbonyl;

R^{11} is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen,

G1, G2, G3, G4 and G5; wherein

G1 is -(CH₂)_r-(CR¹³R¹⁴)_s-R¹²

wherein

r is 0, 1 or 2, and

s is 0 or 1,

R^{12} is selected from the group consisting of hydrogen,

C₁-C₆-alkyl,

C₃-C₆-alkenyl,

C₃-C₆-alkinyl,

C₃-C₈-cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected from the group consisting of N, S and O,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, and

a N, S, O anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring;

R¹³ has the same meaning as *R¹²*, but is selected independently thereof;



R¹⁴ is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,

monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O,


an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, and

an anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms selected from N, S and O;

G2 is selected from the group consisting of



and



D 3

wherein R¹² and R¹⁴ have the above meaning, and Q is a nitrogen-containing heterocycle, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,


saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms;

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is -SO₂- (CH₂)_r-R¹²,

G4 is



wherein

Ar¹ is selected from the group consisting of phenyl, pridyl and naphthyl; and

Ar² is selected from the group consisting of phenyl, pyridyl and naphthyl;


G5 is -COR¹⁵,

wherein

R¹⁵ is selected from the group consisting of trifluoromethyl, C₁-C₆-alkoxy, C₃-C₆-alkenyloxy and benzyloxy; and

wherein aromatic rings in R¹, R⁴, R¹², R¹³, R¹⁴, R¹⁵, Q, Ar¹ and Ar² are unsubstituted or substituted, the substituted rings in R¹, R⁴, R¹², R¹³, R¹⁴, R¹⁵, Q, Ar¹ and Ar² having one to three substituents which are independently selected from the group consisting of halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl, benzyl, hydroxy, C₁-C₆-alkoxy, and a substituted C₁-C₆-alkoxy which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, carboxy, C₂-C₆-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C₁-C₆-alkylamino, and di-(C₁-C₆-alkyl)-amino.

65. (Twice amended) A method of suppressing autoimmune disease in a human or animal body comprising administering to the human or animal body in need thereof an amount of a pharmaceutical composition effective for suppressing autoimmune disease, wherein the pharmaceutical composition includes a compound of general formula (I) or a pharmaceutically acceptable acid addition salt of formula (I)



wherein:

R¹ is selected from the group consisting of hydrogen, halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, C₁-C₄-hydroxyalkyl, hydroxy, C₁-C₄-alkoxy, benzyloxy, C₂-C₄-alkanoyloxy, C₁-C₄-alkylthio, C₂-C₅-alkoxycarbonyl, aminocarbonyl, C₃-C₉-dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy, NR⁵R⁶, and bridged R¹R²; wherein

R⁵ is selected from the group consisting of hydrogen and C₁-C₆-alkyl; and

R⁶ is selected from the group consisting of hydrogen and C₁-C₆-alkyl;

R² is selected from the group consisting of hydrogen, halogen, C₁-C₆-alkyl, trifluoromethyl and hydroxy and bridged R¹R²;

wherein

bridged R¹R² is where R¹R² are adjacent and form a bridge which is selected from the group consisting of - (CH₂)₄-, - (CH=CH)₂- and -CH₂O-CR⁷R⁸-O-; wherein

R⁷ is selected from the group consisting of hydrogen, and C₁-C₆-alkyl; and

R⁸ is selected from the group consisting of hydrogen and C₁-C₆-alkyl;

R³ is selected from the group consisting of hydrogen, halogen and C₁-C₆-alkyl;

R⁴ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, hydroxy, C₁-C₆-alkoxy and benzyloxy;

k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted one to three-fold by C₁-C₃-alkyl, hydroxy, fluorine, cyano, or phenyl, C₄-C₆-alkadienylene,

a substituted C₄-C₆-alkadienylene which is substituted once or twice by C₁-C₃-alkyl, fluorine, cyano, or phenyl, 1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C₁-C₃-alkyl, fluorine, or cyano, and ethinylene;

D is selected from the group consisting of

C₁-C₁₀-alkylene,

a substituted C₁-C₁₀-alkylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

C₂-C₁₀-alkenylene,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

a C₂-C₁₀-alkenylene wherein the double bond is to E,

a substituted C_2-C_{10} -alkenylene which is substituted once or twice by C_1-C_3 -alkyl or hydroxy, wherein the double bond is to E,


P 3
C₃-C₁₀-alkinylene,

a substituted C₃-C₁₀-alkinylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

a C₁ to C₁₀ group selected from the group consisting of C₁-C₁₀-alkylene, C₂-C₁₀-alkenylene and C₃-C₁₀-alkinylene, the C₁ to C₁₀ group having methylene units wherein one to three of the methylene units are isostERICALLY replaced by O, S, NR⁹, CO, SO or SO₂; wherein

R⁹ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, C₂-C₆-acyl and methanesulfonyl;

E is



wherein n and p are, independent of each other, 0, 1, 2, or 3 wherein n + p ≤ 3,

R¹⁰ is selected from the group consisting of hydrogen, C₁-C₃-alkyl, hydroxy, hydroxymethyl, carboxy and C₂-C₇-alkoxycarbonyl;

R¹¹ is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E;

G is selected from the group consisting of hydrogen,
G1, G2, G3, G4 and G5; wherein

P³

G1 is -(CH₂)_r-(CR¹³R¹⁴)_s-R¹²

wherein

r is 0, 1 or 2, and

s is 0 or 1,

R¹² is selected from the group consisting of
hydrogen,

C₁-C₆-alkyl,

C₃-C₆-alkenyl,

C₃-C₆-alkinyl,

C₃-C₈-cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles
which heterocycles contain one to three hetero-atoms selected
from the group consisting of N, S and O, which heterocycles
are bound directly to or over a methylene group,

an anellated bi- and tricyclic aromatic or partially
hydrogenated carbocyclic ring system with 8 to 16 ring atoms
and at least one aromatic ring and the carbocyclic ring and
aromatic ring being bonded with a bond which is either over an
aromatic or a hydrogenated ring and either directly or over a
methylene group, and

an anellated bi- and tricyclic aromatic or partially
hydrogenated heterocyclic ring systems with 8 to 16 ring atoms
and at least one aromatic ring, wherein one to three ring
atoms are selected from N, S and O and the carbocyclic ring

and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group;

B³ R¹³ has the same meaning as R¹², but is selected independently thereof;


R¹⁴ is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, phenyl,


monocyclic aromatic five- and six-membered heterocycles which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

an anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group;


G2 is selected from the group consisting of





D 3

and



wherein R¹² and R¹⁴ have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of

saturated and unsaturated monocyclic, four- to eight-membered heterocycles,


saturated and unsaturated monocyclic, four- to eight-membered heterocycles, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms;

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms, which, aside from an essential nitrogen atom contain one or two further hetero-atoms selected from N, S and O,

G3 is -SO₂-(CH₂)_r-R¹²,

G4 is



wherein

*Ar*¹ is selected from the group consisting of phenyl, pridyl and naphthyl; and

*Ar*² is selected from the group consisting of phenyl, pyridyl and naphthyl;

G5 is -COR¹⁵,

wherein

*R*¹⁵ is selected from the group consisting of trifluoromethyl, C₁-C₆-alkoxy, C₃-C₆-alkenyloxy and benzyloxy; and


wherein aromatic rings in R¹, R⁴, R¹², R¹³, R¹⁴, R¹⁵, Q, Ar¹ and Ar² are unsubstituted or substituted, the substituted rings in R¹, R⁴, R¹², R¹³, R¹⁴, R¹⁵, Q, Ar¹ and Ar² having one to three substituents which are independently selected from the group consisting of halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl, benzyl, hydroxy, C₁-C₆-alkoxy, C₁-C₆-alkoxy, and a C₁-C₆ alkoxy which is entirely or partially substituted by fluorine, benzyloxy, phenoxy, mercapto, C₁-C₆-alkylthio, carboxy, C₂-C₆-alkoxycarbonyl, benzyloxycarbonyl, nitro, amino, mono-C₁-C₆-alkylamino, and di-(C₁-C₆-alkyl)-amino.

66. (Once amended) A method of inhibiting tumor cell growth in a human or animal body comprising administering to the human or animal body in need thereof an amount of a pharmaceutical composition effective for inhibiting tumor cell growth, the pharmaceutical composition comprising (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidine-4-yl)ethyl]-2-propenamide hydrochloride.

93

67. (Once amended) A method of suppressing autoimmune reactions in the human or animal body comprising administering to the human or animal body in need thereof an amount of a pharmaceutical composition effective for suppressing autoimmune reactions, the pharmaceutical composition comprising (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidine-4-yl)ethyl]-2-propenamide hydrochloride.

68. (once amended) A compound of formula (I) and pharmaceutically acceptable acid addition salts of formula (I)



wherein:

R¹ is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl and hydroxy,

R² and R³ are hydrogen,

R⁴ is hydrogen or hydroxy,

k is 0 or 1,

A is selected from the group consisting of C₂-C₄-

alkenylene,

a substituted C₂-C₄-alkenylene which is substituted with fluorine,

*R*³ 1,3-butadienylenes, and

a substituted 1,3-butadienylenes which is substituted with fluorine,

D is selected from the group consisting of C₂-C₆-alkylene,

a C₂-C₆-alkenylene wherein the double bond is to E,

a substituted C₂-C₆-alkinylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy, and



an isostERICALLY replaced C₂-C₆-alkylene wherein a methylene unit of the alkenylene is isostERICALLY replaced by O, NH, N(CH₃) or CO, or a C₂-C₆-alkylene wherein an ethylene group of the alkenylene is isostERICALLY replaced by NH-CO or CO-NH, or a C₂-C₆-alkylene wherein a propylene group of the alkenylene is isostERICALLY replaced by NH-CO-O or O-CO-NH,

E is selected from pyrrolidine, piperidine, 1,2,5,6-tetrahydropyridine, hexahydroazepine, morpholine and hexahydro-1,4-oxazepine,


G is selected from the group consisting of hydrogen, tert-butoxycarbonyl, diphenylphosphinoyl,

- (CH₂)_r - (CR¹³R¹⁴)_s - R¹²,

- C - (CH₂)_r - (CR¹³R¹⁴)_s - R¹²,
||
O



and



wherein r is 0 or 1, and

s is 0 or 1,

R^{12} is selected from the group consisting of hydrogen, methyl, benzyl, phenyl, indenyl, oxoindanyl, naphthyl, tetrahydronaphthyl, fluorenyl, oxofluorenyl, anthryl, dihydroanthryl, oxodihydroanthryl, dioxodihydroanthryl, dibenzocycloheptenyl, dihydrodibenzocycloheptenyl, furyl, thienyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrazinyl, pyrimidinyl, imidazothiazolyl, benzofuryl, benzothienyl, indolyl, oxoindolinyl, dioxoindolinyl, benzoxazolyl, oxobenzoxazolinyl, benzothiazolyl, oxobenzthiazolinyl, benzimidazolyl, oxobenzimidazolinyl, benzofurazanyl, benzotriazolyl, oxazolopyridyl, oxodihydrooxazolopyridyl, thiazolopyridyl, oxodihydrothiazolopyridyl, chromanyl, chromanonyl, benzopyranyl, chromonyl, quinolyl, isoquinolyl, oxodihydroquinolinyl, tetrahydroquinolyl, oxotetrahydroquinolinyl, benzodioxanyl, quinazolinyl, acridinyl, oxodihydroacridinyl, phenothiazinyl, dihydrodibenzoxepinyl, benzocycloheptathienyl, dihydrothienobenzothiepinyl, dihydrodibenzothiepinyl,

oxodihydrodibenzothiepinyl, dihydrodibenzazepinyl,
oxodihydrodibenzazepinyl, octahydrodibenzazepinyl,
benzocycloheptapyridyl, oxobenzocycloheptapyridyl, and
dihydrodibenzothiazepinyl,

⑨ 3


R¹³ is selected from the group consisting of hydrogen,
methyl, benzyl or and phenyl,

R¹⁴ is selected from the group consisting of hydrogen,
hydroxy, methyl, benzyl, phenyl, and

the group consisting of naphthyl, furyl, thienyl,
pyridyl, benzofuryl, benzothienyl, indolyl, benzoxazolyl,
benzothiazolyl, benzimidazolyl, chromanyl, quinolyl and
tetrahydroquinolyl,

wherein Q is selected from the group consisting of
pyrrolidine, piperidine, hexahydroazepine, morpholine, 2,5-
diazabicyclo[2.2.1]heptane, indoline, isoindoline, (1H)-
dihydroquinoline, (1H)-tetrahydroquinoline, (2H)-
tetrahydroisoquinoline, (1H)-tetrahydrobenzo[b]azepine, (1H)-
tetrahydrobenzo[d]azepine, (5H)-tetrahydrobenzo[b]oxazepine,
(5H)-tetrahydrobenzo[b]thiazepine, 1,2,3,4-
tetrahydroacridanone, (5H)-dihydrodibenzazepine, (11H)-
dihydrodibenzo[b,e]oxazepine and (11H)-
dihydrodibenzo[b,e]thiazepine, wherein general formula (I)
does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-
yl)ethyl]-2-propenamide.


69. (Once amended) A method for the production of
compounds having general formula (I)



(I)


the method comprising:

reacting a carboxylic acids of formula (II)



(II)

with compounds of formula (III)



*B*³ wherein

R^1 is selected from the group consisting of hydrogen, halogen, cyano, $\text{C}_1\text{-}\text{C}_6$ -alkyl, trifluoromethyl, $\text{C}_3\text{-}\text{C}_8$ -cycloalkyl, $\text{C}_1\text{-}\text{C}_4$ -hydroxyalkyl, hydroxy, $\text{C}_1\text{-}\text{C}_4$ -alkoxy, benzyloxy, $\text{C}_2\text{-}\text{C}_4$ -alkanoyloxy, $\text{C}_1\text{-}\text{C}_4$ -alkylthio, $\text{C}_2\text{-}\text{C}_5$ -alkoxycarbonyl, aminocarbonyl, $\text{C}_3\text{-}\text{C}_9$ -dialkylaminocarbonyl, carboxy, phenyl, phenoxy, pyridyloxy, NR^5R^6 , and bridged R^1R^2 wherein

R^5 is selected from the group consisting of hydrogen and $\text{C}_1\text{-}\text{C}_6$ -alkyl, and

R^6 is selected from the group consisting of hydrogen and $\text{C}_1\text{-}\text{C}_6$ -alkyl,

R^2 is selected from the group consisting of hydrogen, halogen, $\text{C}_1\text{-}\text{C}_6$ -alkyl, trifluoromethyl and hydroxy and bridged R^1R^2

wherein

bridged R^1R^2 is where R^1R^2 are adjacent and form a bridge which is selected from the group consisting of $-(\text{CH}_2)_4-$, $-(\text{CH}=\text{CH})_2-$ and $-\text{CH}_2\text{O}-\text{CR}^7\text{R}^8-\text{O}-$, wherein

R^7 is selected from the group consisting of hydrogen, and $\text{C}_1\text{-}\text{C}_6$ -alkyl and

R^8 is selected from the group consisting of hydrogen and $\text{C}_1\text{-}\text{C}_6$ -alkyl,

R^3 is selected from the group consisting of hydrogen, halogen and $\text{C}_1\text{-}\text{C}_6$ -alkyl,

R³ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, hydroxy, C₁-C₆-alkoxy and benzyloxy,

R³
k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted one to three-fold by C₁-C₃-alkyl, hydroxy, fluorine, cyano, or phenyl, C₄-C₆-alkadienylene,

a substituted C₄-C₆-alkadienylene which is substituted once or twice by C₁-C₃-alkyl, fluorine, cyano, or phenyl,

1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C₁-C₃-alkyl, fluorine, or cyano, and ethinylene,

D is selected from the group consisting of C₁-C₁₀-alkylene,

a substituted C₁-C₁₀-alkylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

C₂-C₁₀-alkenylene,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,


a substituted C₃-C₁₀-alkinylene,

a substituted C₃-C₁₀-alkinylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

an isosterically replaced C₁ to C₁₀ group selected from the group consisting of C₁-C₁₀-alkylene, C₂-C₁₀-alkenylene and C₃-C₁₀-alkinylene, the isosterically replaced C₁ to C₁₀ group having methylene units and one to three of the methylene units are isosterically replaced by O, S, NR⁹, CO, SO or SO₂, wherein

R^9 is selected from the group consisting of hydrogen, C_1 - C_3 -alkyl, C_2 - C_6 -acyl and methanesulfonyl,

E is



wherein n and p are, independent of each other, 0, 1, or 2, wherein $n + p = 2$,

R^{10} is selected from the group consisting of hydrogen, C_1 - C_3 -alkyl, hydroxy, hydroxymethyl, carboxy and C_2 - C_7 -alkoxycarbonyl,

R^{11} is selected from the group consisting of hydrogen and an oxo group adjacent to the nitrogen atom in E ,

G is selected from the group consisting of hydrogen, G_1 , G_2 , G_3 , G_4 and G_5 , wherein

G_1 is $-(CH_2)_r-(CR^{13}R^{14})_s-R^{12}$

wherein

r is 0, 1 or 2, and

s is 0 or 1,

R¹² is selected from the group consisting of
hydrogen,

D³
C₁-C₆-alkyl,

C₃-C₆-alkenyl,

C₃-C₆-alkinyl,

C₃-C₈-cycloalkyl,

benzyl,

phenyl,

monocyclic aromatic five- and six-membered heterocycles which heterocycles contain one to three hetero-atoms selected from the group consisting of N, S and O, the N, S and O being either bound directly to or over a methylene group,

an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carboxylic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

an anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring systems with 8 to 16 ring atoms and at least one aromatic ring, wherein one to three ring atoms are selected from N, S and O and the carbocyclic ring and aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring, and either directly or over a methylene group,

R¹³ has the same meaning as R¹², but is selected independently thereof,

R¹⁴ is selected from the group consisting of hydrogen,
hydroxy,
methyl,

benzyl,

phenyl,



monocyclic aromatic five- and six-membered heterocycles

P³ which contain one to three hetero-atoms selected from the group consisting of N, S and O and are bound either directly or over a methylene group,


an anellated bi- and tricyclic aromatic or partially hydrogenated carbocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring and the carbocyclic ring and the aromatic ring being bonded with a bond which is either over an aromatic or a hydrogenated ring and either directly or over a methylene group, and

an anellated bi- and tricyclic aromatic or partially hydrogenated heterocyclic ring system with 8 to 16 ring atoms and at least one aromatic ring, which heterocycles contain one to three ring atoms selected from N, S and O and the heterocyclic ring and aromatic ring being bonded with a bond which is over an aromatic or a hydrogenated ring and either directly or over a methylene group,

G2 is selected from the group consisting of



and



wherein R¹² and R¹⁴ have the above meaning, and Q is a nitrogen-containing heterocycle bound over the nitrogen atom, the nitrogen-containing heterocycle being selected from the group consisting of


*P*³ saturated and unsaturated monocyclic, four- to eight-membered heterocycles,

and

saturated and unsaturated bi- or tricyclic, anellated or bridged heterocycles with 8 to 16 ring atoms,

G3 is -SO₂- (CH₂)_r-R¹²,

G4 is



wherein

Ar¹ is selected from the group consisting of phenyl, pridyl and naphthyl and

Ar² is selected from the group consisting of phenyl, pyridyl and naphthyl,

G5 is -COR¹⁵,


wherein

R¹⁵ is selected from the group consisting of trifluoromethyl, C₁-C₆-alkoxy, C₃-C₆-alkenyloxy and benzyloxy, and

P³

wherein aromatic rings in R¹, R⁴, R¹², R¹³, R¹⁴, R¹⁵, Q, Ar¹ and Ar² are unsubstituted or substituted, the substituted rings in R¹, R⁴, R¹², R¹³, R¹⁴, R¹⁵, Q, Ar¹ and Ar² having one to three substituents which are independently selected from the group consisting of halogen, cyano, C₁-C₆-alkyl, trifluoromethyl, C₃-C₈-cycloalkyl, phenyl, benzyl, hydroxy, and C₁-C₆-alkoxy.

70. (Once amended) A compound of formula (I) and pharmaceutically acceptable acid addition salts of formula I



wherein:

R¹ = H or F

k is 0 or 1,

A is selected from the group consisting of C₂-C₆-alkenylene,

a substituted C₂-C₆-alkenylene which is substituted one to three-fold by C₁-C₃-alkyl, hydroxy, fluorine, cyano, or phenyl,

a substituted C₄-C₆-alkadienylene which is substituted once or twice by C₁-C₃-alkyl, fluorine, cyano, or phenyl,

1,3,5-hexatrienylene,

a substituted 1,3,5-hexatrienylene which is substituted by C₁-C₃-alkyl, fluorine, or cyano, and

ethinylene;

R⁴ is selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₆-alkenyl, hydroxy, C₁-C₆-alkoxy and benzyloxy;

*P*³ D is selected from the group consisting of C₁-C₁₀-alkylene,

a substituted C₁-C₁₀-alkylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

C₂-C₁₀-alkenylene,

a substituted C₂-C₁₀-alkenylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,


C₃-C₁₀-alkinylene,

a substituted C₃-C₁₀-alkinylene which is substituted once or twice by C₁-C₃-alkyl or hydroxy,

an isosterically replaced C₁ to C₁₀ group selected from the group consisting of C₁-C₁₀-alkylene, C₂-C₁₀-alkenylene and C₃-C₁₀-alkinylene, the isosterically replaced C₁ to C₁₀ group having methylene units and one to three of the methylene units being isosterically replaced by O, S, NR⁹, CO, SO or SO₂;

R⁹ is selected from [selected from] the group consisting of hydrogen, C₁-C₃-alkyl, C₂-C₆-acyl and methanesulfonyl;



E is



G is selected from the group consisting of

- (CH₂)_r - (CR¹³R¹⁴)_sR¹²,

- C - (CH₂)_r - (CR¹³R¹⁴)_sR¹²,
 ||
 O



$r=0, 1$ or $2,$

$s=0$ or $1,$

R^{12} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_8 -cycloalkyl, benzyl phenyl, and substituted phenyl which substituted phenyl is substituted with one to three substitutents selected from the group consisting of halogen, cyano, C_1-C_6 -alkyl, trifluoromethyl, C_3-C_8 -cycloalkyl, phenyl, benzyl, hydroxy, and C_1-C_6 -alkoxy;

R^{13} is selected from the group consisting of hydrogen, C_1-C_6 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkenyl, C_3-C_8 -cycloalkyl, benzyl phenyl, and substituted phenyl which substituted phenyl is substituted with one to three substitutents selected from the group consisting of halogen, cyano, C_1-C_6 -alkyl, trifluoromethyl, C_3-C_8 -cycloalkyl, phenyl, benzyl, hydroxy, and C_1-C_6 -alkoxy;


R^{14} is selected from the group consisting of hydrogen, hydroxy, methyl, benzyl, and phenyl;

R^{15} is selected from trifluoromethyl, C_1-C_6 -alkoxy, C_3-C_6 -alkenyloxy and benzyloxy;

R^{10} is selected from the group consisting of hydrogen, C_1-C_3 -alkyl, hydroxy, hydroxymethyl, carboxy and C_2-C_7 -alkoxycarbonyl;

and wherein general formula (I) does not include (E)-3-(3-pyridyl)-N-[2-(1-benzylpiperidin-4-yl)ethyl]-2-propenamide.

71. (Once amended) A compound of formula (I) and pharmaceutically acceptable acid addition salts of formula (I)



wherein:

R¹ is selected from the group consisting of hydrogen, fluorine, chlorine, methoxy, methyl, and hydroxy;

R⁴ is hydrogen, methyl or hydroxy;

k is 0 or 1;







A is selected from the group consisting of C₂-C₄-alkenylene,


a substituted C₂-C₄-alkenylene which is substituted with fluorine, cyano, hydroxy and methyl,

1,3-butadienylene, and





a substituted 1,3-butadienylene which is substituted with fluorine;





DEG when together form the structure selected from the group consisting of










⑧³


















09/216, 075

Atty Dkt No. 64978












,




,



,




,






,





09/216,075





Atty Dkt No. 64978






3













P³








D³












P 3











③




















103






































RO³





















B3




P3























77. A method of inhibiting tumor cell growth according to claim 64, wherein DEG is selected from the group consisting of














D³
Cont



















09/216,075

Atty Dkt No. 64978














D 3

cont





09/216, 075





Atty Dkt No. 64978









cont












09/216, 075






Atty Dkt No. 64978




D³
cont











D³
cont


















































































D³
cont






P³
cont


















D³
cont














D 4
82. A method of suppressing autoimmune disease according to claim 65, wherein DEG is selected from the group consisting of





























09/216,075


Atty Dkt No. 64978





















D4
cont








09/216,075





Atty Dkt No. 64978




D4
cont


09/216,075

Atty Dkt No. 64978







,




,




,





,



,








04
cont.






09/216,075





Atty Dkt No. 64978




















DY
cont



















09/216,075





Atty Dkt No. 64978









D4
cont

























D
cont









09/216,075


Atty Dkt No. 64978



09/216,075

Atty Dkt No. 64978





PLEASE ADD THE FOLLOWING NEW CLAIMS:

83. A compound according to claim 42 wherein two adjacent groups of an aromatic ring in the substituted C1-C6-alkoxy may form an additional ring over a methylenedioxy bridge.

84. A compound according to claim 56 wherein two adjacent groups of an aromatic ring in the substituted C1-C6-alkoxy may form an additional ring over a methylenedioxy bridge.

85. A compound according to claim 64 wherein two adjacent groups of an aromatic ring in the substituted C1-C6-alkoxy may form an additional ring over a methylenedioxy bridge.